Release Summary

Spectrum Pharmaceuticals announced surpassing the primary endpoint in the pivotal, registrational Phase 2 BELIEF trial of belinostat, a pan-histone deacetylase (HDAC) inhibitor.

Spectrum Pharmaceuticals, Inc.